Foundayo in Canada: where it stands and what comes next

We built this page for Canadians who saw the US headlines and want the local answer. No hype, no countdown clock. Just the regulatory record, read carefully, plus our own clearly labelled guesses where the record runs out.

Is Foundayo available in Canada right now?

No. Health Canada has not authorised orforglipron. Lilly has one new drug submission under federal review, accepted in January 2026, and no Notice of Compliance has been issued. The two files you may have read about sit with Canada's Drug Agency, which is reviewing coverage for weight management and type 2 diabetes separately.

Here is what that means on the ground. Without a Notice of Compliance (NOC), Health Canada has not issued a Drug Identification Number (DIN). No DIN means a wholesaler cannot sell the product, a pharmacy cannot dispense it, and an insurer has nothing to put on a formulary. A Canadian doctor also cannot prescribe it "off label", because off-label use applies to authorised products. There is no Canadian product yet.

Anyone offering Foundayo in Canada today is offering something outside the normal system. We cover the narrow legal routes (and the ones that are not legal) on our page about getting Foundayo as a Canadian.

Where each Foundayo Canada file sits today

Two federal bodies hold files on orforglipron, and they answer different questions. Health Canada decides whether the drug can be sold. Canada's Drug Agency (CDA-AMC) advises public drug plans on whether to pay for it. Let's take them one at a time.

Health Canada: one new drug submission under review

Health Canada's Submissions Under Review list shows a single entry for orforglipron calcium from Eli Lilly Canada Inc. It is classed as a new active substance under "drugs used in diabetes" (the drug's therapeutic class, which covers the weight indication too), with the submission accepted in January 2026. The list we checked was current to 31 August 2026.

One detail on that entry matters more than it looks. It is flagged as part of an "aligned review" with a health technology assessment organisation. In plain terms, the safety review and the payer review are running side by side instead of one after the other. That is why CDA-AMC is already deep into its work while Health Canada has not yet ruled.

How long can the federal review take? Health Canada's published service standard for a new active substance is 45 days of screening plus 300 days of review, and the clock stops whenever the regulator asks the company questions. Run the arithmetic on a January 2026 filing and a decision lands around the end of 2026 at the earliest. That is our calculation, not a published target. Our dated orforglipron approval tracker keeps the full chronology.

Canada's Drug Agency: two reimbursement files, both Pre-NOC

CDA-AMC opened two separate projects because Lilly asked for coverage in two different populations. Both list the brand name as "TBC" and both record the NOC status at filing as Pre NOC. The weight management file is further along, according to the agency's own orforglipron project page.

Read the scheduled dates as plans, not promises. Agencies move dates. Still, they tell you what to watch: the first public signal on whether Canada's payers like this drug for weight loss is due in late November 2026.

What has to happen before a Canadian pharmacy can stock Foundayo

People often treat "approved" and "available" as one event. In Canada they are several events, run by different organisations, and only the first one is required for a cash-paying patient to fill a prescription. Here is the full chain.

1. Notice of Compliance, DIN and the Canadian product monograph

Health Canada issues the NOC once it is satisfied the benefits outweigh the risks for the proposed use. The DINs for each tablet strength are issued with it, and the Canadian product monograph becomes the official label here. The monograph can differ from the US label on indications, warnings or dose wording, so do not assume the US rules carry over word for word.

2. Lilly's launch decision and supply

An NOC permits sale. It does not force it. The company still has to ship product into Canadian distribution, and the gap can be short or very long. Zepbound reached Canadian pharmacies within about two months of its NOC. Wegovy took about two and a half years, largely because global demand outran supply.

3. PMPRB price ceiling

Patented medicines in Canada fall under the Patented Medicine Prices Review Board, which checks the Canadian list price against prices in eleven comparator countries named in the regulations (Australia, Belgium, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden and the United Kingdom). The United States is not on that list. The board does not block a launch, but it caps how high the Canadian price can go.

4. Canada's Drug Agency recommendation (and INESSS in Québec)

CDA-AMC's expert committee recommends whether public plans should pay, for whom and on what conditions. Québec runs its own assessment through INESSS. A "do not reimburse" result does not stop a drug being sold. It just closes the door to public plans for that indication.

5. pan-Canadian Pharmaceutical Alliance negotiation

The pCPA only negotiates after a positive CDA-AMC or INESSS recommendation. It bargains with the manufacturer for all participating public plans at once and aims to finish a standard negotiation within 90 business days. Either side can walk away, and for weight drugs that has happened.

6. Provincial and territorial listing

Each province and territory then decides on its own formulary listing and criteria. Two Canadians with the same diagnosis can get different answers depending on where they live.

7. Private insurers and plan sponsors

Private plans can list a drug as soon as it has a DIN. They do not have to wait for CDA-AMC. Day to day, the employer or union that funds the plan decides whether whole drug categories, like weight management, are covered at all.

How long these steps took for Wegovy and Zepbound in Canada

The best predictor of the Foundayo path in Canada is what happened to the two weight-management injections that came before it. Here is the record, from the regulator's and the agencies' own documents.

Three lessons jump out. First, the Health Canada review for Wegovy ran just under a year from filing to NOC, which is roughly what the service standard predicts. Second, the NOC-to-pharmacy gap swung from about two months to about two and a half years, and that gap was about supply, not regulation. Third, public coverage for weight loss has been narrow every time. Both CDA-AMC recommendations limited coverage to a high-risk slice of the approved population and demanded a lower price.

The Wegovy story is the cautionary one. According to the BC PharmaCare decision, Novo Nordisk told the pCPA it would no longer seek public coverage of Wegovy in Canada, and the province made it a non-benefit in December 2025. Four years after the NOC, a Canadian on a public plan still had no Wegovy coverage for weight loss.

Our take: orforglipron has two things going for it that Wegovy lacked. The aligned review means CDA-AMC advice could arrive close to the NOC instead of a year later, and Lilly has already shown with Zepbound that it can stock Canadian shelves within about two months of an approval. A tablet stored at room temperature (per the US label) should also be easier to supply at scale than an injection pen. We would not bet on a two-year supply gap this time. We would not bet on broad public coverage either.

Foundayo Canada coverage outlook: public plans vs private insurance

This is the question most readers actually care about, so let's be honest about what is fact and what is forecast. The facts come first.

Public drug plans

For the weight indication, the record above is not encouraging. CDA-AMC estimated Wegovy would cost about $5,066 per patient per year at list price and found it was not good value to public plans without a price cut. The Zepbound recommendation, a year later, again covered only a subgroup. Lilly's own requested criteria for orforglipron cover everyone with a BMI of 30 or more (or 27 with a weight-related condition). Expect CDA-AMC to narrow that.

The diabetes file is a different story. There, Lilly asked for coverage alongside metformin-based regimens, the same kind of slot older diabetes drugs compete for, and the comparison is blood sugar control rather than weight loss alone.

Our take: if any Canadian public plan pays for Foundayo in the first year or two, we think it will be for type 2 diabetes, not weight management. A weight-loss listing, if it comes, will likely carry criteria like prior heart disease or prediabetes, a documented weight-loss response at one year, and a confidential price deal.

One more factor is new this year: cheaper semaglutide. Health Canada authorised the first generic semaglutide for weight management on 29 June 2026 (Apotex's Sevmia) and said six more generic semaglutide submissions were under review. BC has also said it will review generic semaglutide submissions when they reach the market. When a generic injection is the comparator, a new brand pill has to justify its price against a much lower bar. That cuts against generous public coverage for orforglipron.

Private insurance

Private coverage is where most working Canadians will get their answer, and it is moving in the right direction. A 2026 International Foundation of Employee Benefit Plans survey, reported by Benefits and Pensions Monitor, found that 37% of Canadian employers now cover GLP-1 drugs for weight loss, up from 17% in 2024. Among employers that do not, 73% exclude them through a carve-out.

So check two things in your plan booklet now: whether weight-management drugs are carved out as a class, and whether your insurer uses prior authorisation for GLP-1s. If both answers are favourable for Wegovy or Zepbound, your odds for Foundayo are decent once it has a DIN. Nobody can adjudicate a claim before then.

And the price itself? Nobody knows the Canadian figure yet. For reference only, Lilly's US self-pay price starts at US$149 a month for the starter dose, and our orforglipron cost breakdown explains how a Canadian price gets set.

What Canadians can use while Foundayo is under review

Waiting is a choice, not a requirement. Several GLP-1 medicines are already authorised in Canada. Wegovy and Zepbound are weekly injections authorised for chronic weight management, and generic semaglutide for weight management now exists too. Rybelsus is the one authorised oral GLP-1, but its Canadian monograph covers adults with type 2 diabetes (blood sugar control and cardiovascular risk reduction), not weight management, and it comes with strict empty-stomach dosing rules. We compare the two pills in our Foundayo versus Rybelsus breakdown.

Which option fits you is a conversation for a Canadian prescriber. For the practical side (prescriptions, clinical trials, what the border rules allow), see how to get Foundayo or a stand-in today.

Foundayo in Canada: what to watch next and what to ignore

Three public events will tell you the most. Watch them in this order.

• The CDA-AMC draft recommendation for weight management, scheduled for posting on 19 November 2026. It is the first public read on coverage.
• The orforglipron entry dropping off Health Canada's Submissions Under Review list. It means the file has left active review.
• A Notice of Compliance and DINs in Health Canada's Drug Product Database. Only then can Lilly announce a Canadian launch date.

Ignore countdown clocks and "launching next month" claims. Health Canada does not publish target decision dates for individual drugs. And be wary of anyone selling Foundayo to Canadians now: an unauthorised tablet from an unknown source is not a shortcut worth your health.

How we keep this page honest

Every status claim here traces to a document listed in the sources below: Health Canada's review list, CDA-AMC project pages and recommendations, BC PharmaCare's decision, Lilly and Novo Nordisk announcements, and a published employer survey. Where we offer opinion, we label it. We recheck the federal files on a schedule and log every change on our Canadian orforglipron tracker, so if this page and the tracker ever disagree, the newer date wins.